Reprogramming cellular senescence and aging clocks for advanced cancer immunotherapy

Area of Science:

• Oncology
• Geroscience
• Cellular Biology

Background:

• Cellular senescence, initially defined by cell cycle arrest, now includes broader phenotypes regulated by p53-p21CIP1 and p16INK4A-Rb pathways.
• Senescent cells influence cancer by inhibiting early tumors but promoting advanced malignancy through secretory and immunomodulatory functions.
• Persistent senescent cells can cause chronic inflammation, immune escape, and fibrosis, impacting the tumor microenvironment.

Purpose of the Study:

• To review the molecular basis, roles, and therapeutic implications of cellular senescence in cancer.
• To explore the connection between aging clocks, biological age, and cancer susceptibility.
• To discuss current and future therapeutic strategies targeting senescent cells for cancer treatment.

Main Methods:

• Literature review of cellular senescence, tumor microenvironment, aging clocks, and cancer therapeutics.
• Analysis of molecular pathways regulating senescence (p53-p21CIP1, p16INK4A-Rb).
• Examination of senolytic agents and aging clock metrics in cancer therapy.

Main Results:

• Senescent cells accumulate in the tumor microenvironment, secreting pro-inflammatory cytokines that alter immune surveillance and extracellular matrix.
• Aging clocks distinguish biological from chronological age, refining understanding of individual cancer susceptibility.
• Senolytic agents and aging clock-tailored immunotherapies show promise for treating age-related cancers.

Conclusions:

• Cellular senescence is a critical factor in cancer development and progression, with significant implications for therapy.
• Aging clocks offer a novel approach to personalize cancer care, especially for older patients.
• Bridging senescence biology, geroscience, and oncology can transform cancer treatment towards more personalized and age-conscious strategies.